Evidence map›Paper›PMID 41292891›Full record

ArticlebioRxiv : the preprint server for biology2025

Effects and mechanisms of monoclonal and polyclonal human antibodies in protection of humanized mice from HIV-1 challenge.

Urjeet S Khanwalkar, Jennifer Fields, Joshua A Wiener, Marissa L Lindman, Alejandro B Balazs, Michael S Seaman, Lindsey R Baden, Stephen R Walsh, Steven N Fiering, Yina H Huang and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Urjeet S KhanwalkarThayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Jennifer FieldsDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Joshua A WienerThayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Marissa L LindmanThayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Alejandro B BalazsRagon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0002-1767-3944
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Lindsey R BadenDepartment of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Stephen R WalshDepartment of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-0817-9370
Steven N FieringDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Yina H HuangDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Margaret E AckermanThayer School of Engineering, Dartmouth College, Hanover, NH, USA.ORCID 0000-0002-4253-3476

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
Structure-Function Analytics CoreP01AI162242 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2021 to 2025
$22.2M
Gates Foundation INV-036842NCI NIH HHS P30 CA023108NIAID NIH HHS P01 AI162242
6 · The paper itself

Abstract

Recent clinical trials of both active and passive immunization demonstrate the barriers to the successful development of efficacious preventative HIV-1 vaccines and prophylactic antibody treatments. More facile means to explore these interventions in preclinical models could fill key gaps in knowledge and contribute to identifying and optimizing the most promising interventions. Here we report simple adaptations to standard virus challenge strategies in the humanized mouse model that support evaluation of antibody-mediated protection from infection with fewer high stakes design choices and demonstrate evaluation of protection afforded by polyclonal human serum IgG antibodies (pAbs) and monoclonal antibodies (mAbs) with variable pharmacokinetic (PK) and functional profiles. Using these adaptations, we observed that both neutralization and Fc-mediated effector functions contribute to the

Identifiers

PMID41292891
PMCPMC12642432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.